ARRIEN PHARMACEUTICALS LLC has a total of 31 patent applications. Its first patent ever was published in 2012. It filed its patents most often in United States, EPO (European Patent Office) and WIPO (World Intellectual Property Organization). Its main competitors in its focus markets pharmaceuticals and organic fine chemistry are SOPHARMA SA, LEBLOND BERTRAND and THERAVANCE BIOPHARMA R&D IP LLC.
# | Country | Total Patents | |
---|---|---|---|
#1 | United States | 13 | |
#2 | EPO (European Patent Office) | 5 | |
#3 | WIPO (World Intellectual Property Organization) | 5 | |
#4 | Canada | 3 | |
#5 | Hungary | 2 | |
#6 | Australia | 1 | |
#7 | Japan | 1 | |
#8 | Serbia | 1 |
# | Industry | |
---|---|---|
#1 | Pharmaceuticals | |
#2 | Organic fine chemistry |
# | Technology | |
---|---|---|
#1 | Heterocyclic compounds | |
#2 | Therapeutic chemical compounds | |
#3 | Medical preparations | |
#4 | Acyclic or carbocyclic compounds |
# | Name | Total Patents |
---|---|---|
#1 | Vankayalapati Hariprasad | 30 |
#2 | Yerramreddy Venkatakrishnareddy | 24 |
#3 | Appalaneni Rajendra P | 16 |
#4 | Gangireddy Paramareddy | 7 |
#5 | Talluri Sureshkumar | 6 |
#6 | Ganipisetty Venu Babu | 6 |
#7 | Krishna Reddy Y Venkata | 3 |
#8 | Appalaneni Rajendra | 1 |
#9 | Venkatakrishnareddy Yerramreddy | 1 |
#10 | Hariprasad Vankayalapati | 1 |
Publication | Filing date | Title |
---|---|---|
WO2020087024A1 | Pyrazolyl compounds and methods of use thereof | |
US2015072980A1 | Substituted 2,3-dihydro-1H-inden-1-one retinoic acid-related orphan nuclear receptor antagonists for treating multiple sclerosis | |
US2014315909A1 | Substituted pyrrolo[2,3-b]pyridines as ITK and JAK inhibitors | |
US2014256704A1 | Substituted 1H-pyrrolo [2, 3-b] pyridine and 1H-pyrazolo [3, 4-b] pyridine derivatives as salt inducible kinase 2 (SIK2) inhibitors | |
WO2012135631A1 | Substituted 5-(pyrazin-2-yl)-1h-pyrazolo [3, 4-b] pyridine and pyrazolo [3, 4-b] pyridine derivatives as protein kinase inhibitors |